Data gathered: November 24
AI Stock Analysis - Catalyst Pharmaceuticals (CPRX)
Analysis generated October 14, 2024. Powered by Chat GPT.
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare neurological diseases. The company's primary focus is on treatments for rare, chronic neuromuscular disorders such as Lambert-Eaton Myasthenic Syndrome (LEMS) and congenital myasthenic syndromes (CMSs).
Stock Alerts - Catalyst Pharmaceuticals (CPRX)
 |
Catalyst Pharmaceuticals | November 22 Insider Alert: MCENANY PATRICK J is continuing selling shares |
|
Catalyst Pharmaceuticals | November 15 Price is down by -5.3% in the last 24h. |
|
Catalyst Pharmaceuticals | November 14 Price is down by -5.4% in the last 24h. |
|
Catalyst Pharmaceuticals | November 14 Insider Alert: MCENANY PATRICK J is selling shares |
Alternative Data for Catalyst Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 3 | Sign up | Sign up | Sign up |
| Sentiment | 94 | Sign up | Sign up | Sign up |
| Webpage traffic | 9,000 | Sign up | Sign up | Sign up |
| Employee Rating | 80 | Sign up | Sign up | Sign up |
| Google Trends | 14 | Sign up | Sign up | Sign up |
| Patents | 2 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 13 | Sign up | Sign up | Sign up |
| Facebook Followers | 2,879 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 15,573 | Sign up | Sign up | Sign up |
| Twitter Followers | 919 | Sign up | Sign up | Sign up |
| Twitter Mentions | 16 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 39 | Sign up | Sign up | Sign up |
| Business Outlook | 100 | Sign up | Sign up | Sign up |
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of therapies for people with rare debilitating diseases, chronic neuromuscular and neurological diseases.
| Price | $21.48 |
| Target Price | Sign up |
| Volume | 863,050 |
| Market Cap | $2.56B |
| Year Range | $14.68 - $23.93 |
| Dividend Yield | 0% |
| PE Ratio | 17.9 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Catalyst Pharmaceuticals to Participate in Upcoming Investor ConferencesNovember 19 - GlobeNewswire |
|
 |
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth StockNovember 14 - Yahoo |
 |
Truist Financial Issues Positive Forecast for Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock PriceNovember 13 - ETF Daily News |
 |
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to WorkNovember 12 - Yahoo |
 |
Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings May Just Be The Starting PointNovember 12 - Yahoo |
 |
Catalyst Pharmaceuticals (NASDAQ:CPRX) vs. Antibe Therapeutics (OTCMKTS:ATBPF) Critical AnalysisNovember 12 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 129M | 65M | 64M | 44M | 60M | 0.000 |
| Q2 '24 | 123M | 56M | 67M | 41M | 64M | 0.330 |
| Q1 '24 | 99M | 69M | 30M | 23M | 36M | 0.190 |
| Q4 '23 | 111M | 67M | 44M | 35M | 51M | 0.310 |
| Q3 '23 | 103M | 48M | 55M | -31M | -29M | -0.290 |
Insider Transactions View All
| MCENANY PATRICK J filed to sell 4,478,169 shares at $21.3. November 21 '24 |
| MCENANY PATRICK J filed to sell 4,478,169 shares at $21.2. November 21 '24 |
| MCENANY PATRICK J filed to sell 4,478,169 shares at $23.4. November 13 '24 |
| MCENANY PATRICK J filed to sell 4,478,169 shares at $23.2. November 13 '24 |
| MCENANY PATRICK J filed to sell 4,478,169 shares at $23.5. November 13 '24 |
Similar companies
Read more about Catalyst Pharmaceuticals (CPRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & business outlook.
What is the Market Cap of Catalyst Pharmaceuticals?
The Market Cap of Catalyst Pharmaceuticals is $2.56B.
What is Catalyst Pharmaceuticals' PE Ratio?
As of today, Catalyst Pharmaceuticals' PE (Price to Earnings) ratio is 17.9.
What is the current stock price of Catalyst Pharmaceuticals?
Currently, the price of one share of Catalyst Pharmaceuticals stock is $21.48.
How can I analyze the CPRX stock price chart for investment decisions?
The CPRX stock price chart above provides a comprehensive visual representation of Catalyst Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Catalyst Pharmaceuticals shares. Our platform offers an up-to-date CPRX stock price chart, along with technical data analysis and alternative data insights.
Does CPRX offer dividends to its shareholders?
As of our latest update, Catalyst Pharmaceuticals (CPRX) does not offer dividends to its shareholders. Investors interested in Catalyst Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Catalyst Pharmaceuticals?
Some of the similar stocks of Catalyst Pharmaceuticals are Amgen, Gilead Sciences, Inovio Pharmaceuticals, Anavex Life Sciences, and BridgeBio Pharma.
.